ReviewWorld journal of gastroenterology2014
Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
158 citing papers in PubMed, 5 syntheses or guidelines pooled it, 291 citations in OpenAlex.
- Worldwide research trends on theFrontiers in immunology · 2026Pooled it
- First regional consensus on the management ofWorld journal of gastroenterology · 2025Guideline
- Beware Pathological Findings of the Stomach in Patients Undergoing Bariatric Surgery: a Systematic Review and Meta-analysis.Obesity surgery · 2021Pooled it
- The Effect of Helicobacter pylori on Postoperative Outcomes in Patients Undergoing Bariatric Surgery: a Systematic Review and Meta-analysis.Obesity surgery · 2018Pooled it
- Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2015Pooled it
- Efficacy of 10 days high-dose and double-dose rabeprazole-based concomitant therapy for Helicobacter pylori eradication among Lebanese population: a pilot randomized controlled trial.BMC gastroenterology · 2025Trial
- Modulation of the oxidative plasmatic state in gastroesophageal reflux disease with the addition of rich water molecular hydrogen: A new biological vision.Journal of cellular and molecular medicine · 2018Trial
- Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma.Blood cancer journal · 2026Article
- Analysis of intratumoural bacteria: Opportunities and challenges for cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- The relationship between Helicobacter pylori severity and hematological parameters in pediatric patients with celiac disease.BMC pediatrics · 2026Observational
- Immunoinformatic-driven design of a multi-epitope vaccine againstBiochemistry and biophysics reports · 2026Article
- Article
- Effect of laparoscopic sleeve gastrectomy on heart remodeling and right ventricular function.Caspian journal of internal medicine · 2026Article
- Endoscopic submucosal dissection in Helicobacter pylori-negative early gastric adenocarcinoma with diffuse large B-cell lymphoma: a two-case report and literature review.Discover oncology · 2025Article
- Development and validation of novel diagnostic recombinant surface antigen D5 and cytotoxic gene pathogenesis island Cag11 protein for Helicobacter pylori.Scientific reports · 2025Article
- Detection ofJournal of imaging · 2025Article
- Unveiling the intratumor microbiome in liver cancer: Current insights and prospective applications.Clinical and molecular hepatology · 2025Review
- Association ofJGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Emerging roles of intratumoral microbiota: a key to novel cancer therapies.Frontiers in oncology · 2025Review
- Article
98 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori (H. pylori) is an extremely common, yet underappreciated, pathogen that is able to alter host physiology and subvert the host immune response, allowing it to persist for the life of the host. H. pylori is the primary cause of peptic ulcers and gastric cancer. In the United States, the annual cost associated with peptic ulcer disease is estimated to be $6 billion and gastric cancer kills over 700000 people per year globally. The prevalence of H. pylori infection remains high (> 50%) in much of the world, although the infection rates are dropping in some developed nations. The drop in H. pylori prevalence could be a double-edged sword, reducing the incidence of gastric diseases while increasing the risk of allergies and esophageal diseases. The list of diseases potentially caused by H. pylori continues to grow; however, mechanistic explanations of how H. pylori could contribute to extragastric diseases lag far behind clinical studies. A number of host factors and H. pylori virulence factors act in concert to determine which individuals are at the highest risk of disease. These include bacterial cytotoxins and polymorphisms in host genes responsible for directing the immune response. This review discusses the latest advances in H. pylori pathogenesis, diagnosis, and treatment. Up-to-date information on correlations between H. pylori and extragastric diseases is also provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.